DTPa-IPV/Hib vaccine
Phase 3Vaccine
GSKDTPa-IPV/Hib vaccine is one of 31 biologic programs targeting Hepatitis B. It is currently in Phase 3.
1
Indications
4
Total Trials
0
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
252 competitors in Hepatitis B
#DrugCompanyPhaseTrials
1Viread
GileadPhase 3
YF-Vax
SanofiPhase 3
Virazole
CConrado Roberto Hoffmann Filho
Phase 3
Immunoglobulins
CSL BehringPhase 3
Recombinant Hepatitis B Vaccine
NovartisPhase 3
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Hepatitis B Adjuvanted Vaccine
GSKPhase 3
HEPLISAV
DDynavax Technologies Corporation
Phase 3
Vemlidy
GileadPreclinical
HB-AS02V
HHenogen
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immunogenicity3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DTPa-IPV/Hib vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]